Cipargamin

Novartis 

Legend
Product vision
  • Uncomplicated malaria treatment and resistance management
  • Severe malaria treatment
MoA
  • PfATP4 inhibitor
Key features
  • Novel mechanism of action for resistance management
  • Potentially simplified dosing schedule
  • Very rapid killing of parasites
  • Potential for transmission-blocking activity
Challenges
  • Identifying partner compound for oral and intravenous (i.v.) development programme
  • Establish novel clinical endpoint for severe malaria
Status
  • Phase II oral malaria patient study and parenteral Good Laboratory Practice safety study completed
  • First-in-human study with intravenous formulation completed
Next milestone
  • Initiate phase II monotherapy (i.v.) study in severe malaria patients
Previously
  • NITD609, KAE609. Novartis in discovery partnership with MMV,  Wellcome Trust and the Swiss Tropical and Public Health Institute
MMV Project Director
  • Dr Gonzalo Acuña